{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:41Z","timestamp":1793726021890,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shanxi Provincial Human Resources and Social Security Department"},{"name":"Scientific Research Project of Shanxi Health Planning Committee","award":["201601042"],"award-info":[{"award-number":["201601042"]}]},{"name":"Scientific Research Foundation for the Returned Overseas Scholar of Shanxi Province"},{"name":"Scientific Research Project of Shenzhen University General Hospital","award":["0000040522"],"award-info":[{"award-number":["0000040522"]}]},{"name":"Key Research and Development Project (Guide) of Shanxi Province","award":["201803D421067"],"award-info":[{"award-number":["201803D421067"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.intimp.2019.105912","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T08:32:36Z","timestamp":1571905956000},"page":"105912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis"],"prefix":"10.1016","volume":"77","author":[{"given":"Min","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2019.105912_b0005","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar3761","article-title":"Serum level of soluble CX3CL1\/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity","volume":"14","author":"Suzuki","year":"2012","journal-title":"Arthritis. Res. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2019.105912_b0010","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10067-012-2075-4","article-title":"Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis","volume":"31","author":"Wang","year":"2012","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2019.105912_b0015","first-page":"94","article-title":"Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive?","volume":"2","author":"Zheng","year":"2013","journal-title":"Am. J. Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.105912_b0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2019.105912_b0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4137\/CMAMD.S10272","article-title":"Phenotypes of peripheral Blood Lymphocytes and cytokine expression in polymyositis and Dermatomyositis before Treatment and after clinical Remission","volume":"5","author":"Shimojima","year":"2012","journal-title":"Clin. Med. Insights. Arthritis. Musculoskelet Disord."},{"key":"10.1016\/j.intimp.2019.105912_b0030","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/717808","article-title":"Serum Interleukin-6 Expression Level and Its Clinical Significance in Patients with Dermatomyositis","volume":"2013","author":"Yang","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2019.105912_b0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cyto.2006.07.023","article-title":"Proinflammatory cytokines (TNF-and IL-6) in Egyptian patients with SLE: its correlation with disease activity","volume":"35","author":"Sabry","year":"2006","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.intimp.2019.105912_b0040","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/03009742.2014.956141","article-title":"Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies","volume":"44","author":"Notarnicola","year":"2015","journal-title":"Scand. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2019.105912_b0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2249.2006.03180.x","article-title":"Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies","volume":"146","author":"Tucci","year":"2006","journal-title":"Clin. Exp. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2019.105912_b0050","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/imt.14.83","article-title":"Beyond regulatory T cells: the potential role for IL-2 to deplete Tfollicular helper cells and treat autoimmune diseases","volume":"6","author":"Ballesteros-Tato","year":"2014","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.intimp.2019.105912_b0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2019.105912_b0060","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"13","key":"10.1016\/j.intimp.2019.105912_b0065","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.4103\/0366-6999.235114","article-title":"Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus","volume":"131","author":"Shao","year":"2018","journal-title":"Chin. Med. J. (Engl)"},{"issue":"1","key":"10.1016\/j.intimp.2019.105912_b0070","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22209","article-title":"Red blood cell distribution width and neutrophil to lymphocyte ratio are correlated with disease activity of dermatomyositis and polymyositis","volume":"32","author":"Gao","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"issue":"6","key":"10.1016\/j.intimp.2019.105912_b0075","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bjd.17079","article-title":"Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis","volume":"179","author":"Chen","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2019.105912_b0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2019.105912_b0085","article-title":"New onset of dermatomyositis\/polymyositis during anti-TNF-\u03b1 therapies: a systematic literature review","volume":"179180","author":"Brunasso","year":"2014","journal-title":"Sci. World J."},{"issue":"1","key":"10.1016\/j.intimp.2019.105912_b0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","article-title":"Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota","volume":"146","author":"Bendewald","year":"2010","journal-title":"Arch. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2019.105912_b0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1759720X11424460","article-title":"Juvenile dermatomyositis: new insights and new treatment strategies","volume":"4","author":"Martin","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2019.105912_b0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00005792-200303000-00002","article-title":"Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy","volume":"82","author":"Viguier","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2019.105912_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/472624","article-title":"Soluble IL-2 receptor: a biomarker for assessing myositis activity","author":"Tournadre","year":"2014","journal-title":"Dis. Markers"},{"issue":"3","key":"10.1016\/j.intimp.2019.105912_b0110","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4049\/jimmunol.182.3.1541","article-title":"Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses","volume":"182","author":"Maier","year":"2009","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2019.105912_b0115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-016-0617-5","article-title":"Low-dose IL-2 in the treatment of lupus","volume":"18","author":"Mizui","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2019.105912_b0120","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2019.105912_b0125","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1038\/s41419-017-0010-y","article-title":"Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis","volume":"8","author":"John","year":"2017","journal-title":"Cell. Death. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2019.105912_b0130","doi-asserted-by":"crossref","first-page":"C714","DOI":"10.1152\/ajpcell.00418.2001","article-title":"Tumor necrosis factor-inhibits myogenesis through redoxdependent and -independent pathways","volume":"283","author":"Langen","year":"2002","journal-title":"Am. J. Physiol. Cell. Physiol."},{"issue":"11","key":"10.1016\/j.intimp.2019.105912_b0135","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis. Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2019.105912_b0140","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle. Nerve."},{"issue":"12","key":"10.1016\/j.intimp.2019.105912_b0145","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/rheumatology\/key222","article-title":"Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment","volume":"57","author":"Helmers","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2019.105912_b0150","first-page":"101","article-title":"Dermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics)","volume":"53","author":"Shinjo","year":"2013","journal-title":"Rev. Bras. Reumatol."},{"issue":"25","key":"10.1016\/j.intimp.2019.105912_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL- 2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2019.105912_b0160","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.intimp.2019.105912_b0165","doi-asserted-by":"crossref","first-page":"e0155381","DOI":"10.1371\/journal.pone.0155381","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.intimp.2019.105912_b0170","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1164\/rccm.200812-1936OC","article-title":"Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis","volume":"179","author":"Kotsianidis","year":"2009","journal-title":"Am. J. Respir. Crit. Care. Med."},{"issue":"2","key":"10.1016\/j.intimp.2019.105912_b0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/08830185.2013.863303","article-title":"Forkhead box P3: the peacekeeper of the immune system","volume":"33","author":"Passerini","year":"2014","journal-title":"Int. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2019.105912_b0180","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri3650","article-title":"FOXP3 and scurfy: how it all began","volume":"14","author":"Ramsdell","year":"2014","journal-title":"Nat. Rev. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691931570X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691931570X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:12:18Z","timestamp":1761585138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757691931570X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":36,"alternative-id":["S156757691931570X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105912","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105912"}}